These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2897988)

  • 1. Platelet aggregation in hypertension and the effects of antihypertensive treatment.
    Nyrop M; Zweifler AJ
    J Hypertens; 1988 Apr; 6(4):263-9. PubMed ID: 2897988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers.
    Winther K; Gleerup G; Hedner T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S41-4. PubMed ID: 1725542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on intervention in arterial hypertension. Recommendations by experts and practical antihypertensive therapy. German Hypertension League].
    Trenkwalder P
    Fortschr Med; 1999 Feb; 117(6):24, 25-8, 30 passim. PubMed ID: 10095298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prazosin GITS, atenolol, nifedipine SR, and enalapril on ADP-induced platelet aggregation.
    Patki KC; Joglekar SJ; Kamat SK; Thatte UM; Yeolekar ME; Rege NN; Dahanukar SA; Nanivadekar AS
    J Assoc Physicians India; 1998; Suppl 1():26-9. PubMed ID: 11229106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension and calcium antagonists.
    Doyle AE
    Clin Exp Pharmacol Physiol Suppl; 1982; 6():103-6. PubMed ID: 6749350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effect of losartan on platelet aggregation in patients with hypertension.
    Akdemir R; Ozhan H; Yazici M; Gunduz H; Duran S; Gurel C; Ozdas S; Uyan C; Basar I; Ulutin T
    Heart Vessels; 2004 Jul; 19(4):167-71. PubMed ID: 15278389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of lotensin and nitrendipine on plasma fibrinogen and platelet aggregation in hypertensive patients].
    Pan R; Sun M; Zhou H; Jia Z
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(1):87-9. PubMed ID: 10681808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of antihypertensive drugs on lipid metabolism. Part I. Diuretics, beta-blockers, calcium antagonists].
    Martynov AI; Ostroumova OD; Mamaev VI; Rybkina TE; Kuznetsov VI; Tikhonova LIa; Smirnova MV
    Klin Med (Mosk); 2001; 79(8):8-12. PubMed ID: 11588795
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of calcium antagonists with other antihypertensive agents.
    Doyle AE
    J Hypertens Suppl; 1985 Dec; 3(3):S531-3. PubMed ID: 2908821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of nitrates and beta-blockers on platelet aggregation in patients with coronary heart disease].
    Wlazłowski R; Kruszyński G; Goch JH
    Pol Merkur Lekarski; 2000 Feb; 8(44):77-9. PubMed ID: 10808734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive persistence and drug class.
    Marentette MA; Gerth WC; Billings DK; Zarnke KB
    Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Stress-associated hypertension in the work place: results of the STARLET project].
    Lüders S; Hammersen F; Kulschewski A; Frerichs A; Frieg R; Hahnheiser D; Reich G; Schnieders M; Schrandt G; Schrader J
    Dtsch Med Wochenschr; 2006 Nov; 131(46):2580-5. PubMed ID: 17096303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological hypertension therapy].
    Pedersen OL; Christensen KL; Bang LE; Ibsen H; Schultz-Larsen P
    Ugeskr Laeger; 2009 Jun; 171(24):2022-5. PubMed ID: 19523367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
    Sarafidis PA; Bakris GL
    QJM; 2006 Jul; 99(7):431-6. PubMed ID: 16766516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium antagonist and beta blocker regimens found equally effective in hypertensive patients with coronary artery disease.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Jan; 15(2):1, 5-6. PubMed ID: 14994735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.